Last reviewed · How we verify
Allogeneic HB-adMSCs
At a glance
| Generic name | Allogeneic HB-adMSCs |
|---|---|
| Sponsor | Hope Biosciences LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Stem Cells for Erectile Dysfunction Post RALP (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
- HB-adMSCs for the Treatment of Crohn's Disease (PHASE2)
- HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis (PHASE2)
- Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) (PHASE2)
- Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury
- Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogeneic HB-adMSCs CI brief — competitive landscape report
- Allogeneic HB-adMSCs updates RSS · CI watch RSS
- Hope Biosciences LLC portfolio CI